Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
4.700
+0.300 (6.82%)
At close: Apr 24, 2026, 4:00 PM EDT
4.710
+0.010 (0.21%)
After-hours: Apr 24, 2026, 7:51 PM EDT
Prelude Therapeutics Employees
Prelude Therapeutics had 79 employees as of December 31, 2025. The number of employees decreased by 52 or -39.69% compared to the previous year.
Employees
79
Change (1Y)
-52
Growth (1Y)
-39.69%
Revenue / Employee
$153,671
Profits / Employee
-$1,259,468
Market Cap
472.60M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 79 | -52 | -39.69% |
| Dec 31, 2024 | 131 | 3 | 2.34% |
| Dec 31, 2023 | 128 | 6 | 4.92% |
| Dec 31, 2022 | 122 | 6 | 5.17% |
| Sep 30, 2022 | 120 | 7 | 6.19% |
| Jun 30, 2022 | 112 | 12 | 12.00% |
| Mar 31, 2022 | 118 | 13 | 12.38% |
| Dec 31, 2021 | 116 | 48 | 70.59% |
| Sep 30, 2021 | 113 | 58 | 105.45% |
| Jun 30, 2021 | 100 | 49 | 96.08% |
| Mar 31, 2021 | 105 | 54 | 105.88% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 674 |
| Ginkgo Bioworks Holdings | 485 |
| REGENXBIO | 371 |
| 4D Molecular Therapeutics | 196 |
| Entrada Therapeutics | 152 |
| Aura Biosciences | 113 |
| Larimar Therapeutics | 71 |
| Armata Pharmaceuticals | 60 |
PRLD News
- 6 days ago - Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering - GlobeNewsWire
- 6 days ago - Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 - GlobeNewsWire
- 11 days ago - Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer - GlobeNewsWire
- 5 weeks ago - Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting - GlobeNewsWire
- 6 weeks ago - Prelude Therapeutics Transcript: Conference - Transcripts
- 6 weeks ago - Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 - GlobeNewsWire
- 2 months ago - Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor - GlobeNewsWire
- 5 months ago - Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs - GlobeNewsWire